Background-Transapical transcatheter aortic valve implantation is generally perceived to be associated with increased morbidity compared with transfemoral transcatheter aortic valve implantation. We aimed to compare access-related complications and survival using propensity score matching. 
A ortic stenosis is the most common heart valve disease in adults, and valve replacement is the treatment of choice for severe symptomatic aortic stenosis. The mainstay of treatment has been surgical aortic valve replacement, but since the introduction of transcatheter aortic valve implantation (TAVI), these high-risk patients may now be offered an alternative therapeutic option using a less invasive technique without the need for cardiopulmonary bypass. 1 For the purpose of valve delivery, transfemoral and transapical access routes are used most widely. There is a common perception that transapical may result in a higher long-term mortality than transfemoral, and clinical registries, such as SOURCE 1/2, FRANCE2, UK TAVR, SENTINEL, and a large Canadian Registry, [2] [3] [4] [5] [6] [7] [8] [9] [10] have partially shown considerable differences in 30 day mortality. Available published reports directly comparing either access route [11] [12] [13] [14] [15] [16] usually include data of centers with a low volume followed for 30 days and ≤4 year. They report comparable survival rates over a short term 11, 13, 15, 16 and ≤1 year 11, 13 or 4 years 7 with no 12, 14 or small 15 differences in the rates of cerebral ischemic lesions. More recent data report increased mortality rates with transapical-TAVI even after multivariable adjustment. 9, 10 We have adopted both techniques (transapical and transfemoral) in 1 dedicated multidisciplinary team and have TAVIK: Transapical Versus Transfemoral TAVI prospectively documented a consecutive series of 1000 patients who underwent TAVI in our center starting April 2008. In our report we (1) aimed to evaluate and compare accessrelated complications between the transfemoral and transapical approach in a single center with a high TAVI volume and (2) to compare long-term survival with either access route.
Methods
Analyses were based on the prospective, open TAVI-Karlsruhe registry of consecutive patients undergoing TAVI between April 30, 2008 , and April 3, 2012 (4 years). Details of this registry have been published earlier. [17] [18] [19] The study was approved by the local ethics committee and the subjects gave informed consent.
Patient Assignment
Joint discussions between cardiologists and cardiac surgeons established the method of valve replacement/implantation. Patients were assigned to the TAVI group if (1) the logistic EuroSCORE was ≥15 irrespective of age; (2) they had an age ≥75 years, a logistic EuroSCORE <15, but had additional predisposing risks. This risk was defined as (a) prior open heart surgery, (b) additional comorbidities, such as malignancy with a life expectancy of >1 year, liver cirrhosis, severe pulmonary disease with long-term oxygen provision or Karnofsky Performance index between 50 and 70 or (c) frailty 20, 21 (based on subjective assessment); or (3) patients had a porcelain aorta. In addition, patients were considered for TAVI if they had an indication for aortic valve replacement, but denied to undergo surgery. TAVI was not considered if the native aortic valve annulus was not considered appropriate or life expectancy and quality of life were seriously affected by comorbidities, such as malignancy with a <1-year life expectancy, major stroke, dementia with disability, uncontrolled congestive heart failure, or cardiogenic shock.
Access
The decision for either transapical or transfemoral was based on an interdisciplinary consensus by members of the heart team. There was neither a transapical nor transfemoral first approach, and the preferred access route of the referring physician was evaluated by the following criteria: (1) diameter of peripheral vessels; (2) availability of valves (Edwards SAPIEN, CoreValve, Symetis); (3) localization of calcification (valves, marginalized); (4) severity of calcification; (5) anatomic situation (distance between coronaries, plane sinus). Having in mind that TAVI is an evolving field and the reporting period spans 4 years, no clinical trial like triage was consistently applied during the period, but rather the treatment decisions evolved in that period of time based on actual progress of the technique and our experience. No other alternative access routes (subclavian, transaortic, or transcarotid) were performed.
Procedures and Devices
A multidisciplinary team of an interventional cardiologist, cardiac surgeon, anesthesiologist specialized in cardiac surgery together with personnel of the catheterization laboratory and operating room was trained to perform the TAVI procedure.
Patients with severe aortic stenosis considered for an intervention underwent cardiac catheterization, angiographic cardiac and peripheral vessels computed tomography, and a transesophageal echocardiogram. The computed tomography was carefully reviewed to determine both the distance between coronary arteries and the aortic valve annulus and the diameters of the aorta and the iliofemoral vessels. The native aortic valve annulus diameter was measured using computed tomography and also using the transesophageal echocardiogram long-axis view at the level of leaflet insertion.
Both the Edwards SAPIEN and SAPIEN XT THV and Medtronic CoreValve were used in patients suitable for transfemoral access. For a transapical delivery, the Edwards SAPIEN THV or the Symetis ACURATE was used ( Figure 1 ).
Study End Points and Definitions
The primary objective of this analysis was to determine 30 day and long-term mortality in patients undergoing transapical versus transfemoral TAVI. Secondary objectives included the descriptions of 30 day complications using the Valve Academic Research Consortium (VARC) end point definitions version II. 22 The follow-up was conducted on an outpatient basis or by telephone interview.
Statistical Analysis
For the descriptive analysis of the population, means±standard deviations were used. The P value was determined for the full cohort in case of continuous variables and in relative numbers using a t test and in case of counting variables using χ 2 -tests. For the propensity score-matched cohort, means±standard deviations were also used. In case of continuous variables and relative numbers, mean differences were computed (Table 1) . For age and ejection fraction, difference of means was indicated. For the log
WHAT IS KNOWN
• Transfemoral and transapical access routes are used most commonly for transcatheter aortic valve implantation (TAVI); both access routes have distinct advantages.
• Transapical TAVI is perceived to be associated with more complications and a worse prognosis based on several registries.
• This is thought to be associated to the patient risk profile and procedural experience.
WHAT THE STUDY ADDS
• In our experience, there was no significant difference in short-or long-term mortality in patients undergoing transfemoral or transapical TAVI.
• Patients undergoing transapical TAVI at our center, by an experienced heart team, had comparable procedural outcomes to patients undergoing transfemoral TAVI, with few minor differences in specific adverse events. EUROSCORE I, it was normalized. For counting variables, the population number-normalized absolute differences were used. For the VARC II complications, the relative numbers were given for the transapical and transfemoral patient groups, including the odds ratios (OR) with 95% confidence intervals (CI) and P values of χ 2 -tests for the full and propensity-matched cohort. Survival statistics were conducted using the Kaplan-Meier statistics, log-rank tests, and hazard ratios (HR), including 95% CIs. Censorship is described. Additionally, a Cox proportional hazard model in the stepwise procedure was used in the full model with entry probability 0.10 and staying probability 0.05 to gain information of prognostic factors.
Propensity score matching was used to adjust for differences in baseline characteristics and potential confounders. 23 First, a propensity score for each patient was built using multivariable logistic regression, with the type of intervention as the end point (transapical versus transfemoral). The following covariates were selected to calculate the propensity score: age, sex, ejection fraction, peripheral arterial disease, coronary artery disease, carotid stenosis, redo intervention, neurological dysfunction, pulmonary hypertension, recent myocardial infarction, chronic obstructive pulmonary disease, mitral valve vitium, serum creatinine, critical preoperative state, urgent surgery, and logistic EuroSCORE I. The C-statistic for the propensity score model was 0.78, indicating good discrimination. The Hosmer-Lemeshow goodness-of-fit test P value was 0.8592, confirming good calibration and fit of the multivariable model that estimated the propensity score. Second, for the development of propensity score-matched pairs, 1:1 matching was performed following the suggestion by Rosenbaum and Rubin 24 and Austin 25 who recommend the use of the caliper equal to 0.2 of the standard deviation of the logit of the propensity score, which was in our case c=0.007625. A second matching as a landmark analysis was applied in this population using the data of all patients surviving 30 days and the information of the VARC II variables ending in a new subset of 1:1 matching. Statistical analysis was performed using SAS 9.2.
Results
Out of 1003 documented patients, 1000 were considered evaluable for the present analysis ( Figure 1 ). The remaining 3 patients had concomitant interventions of the mitral valve (n=2) or an atrial septal defect (n=1). Patients were not considered for surgery because of a EuroSCORE >15 (n=581), porcelain aorta (52), dementia (33) , active or inactive cancer (140), liver cirrhosis (12), severe COPD (n=16), post cardiac surgery (192), severe pulmonary hypertension (72), EF <30% (65), and surgery denial (n=567).
A total of 413 patients received TAVI using the transapical route (Edwards SAPIEN/SAPIEN XT THV n=402; Symetis Acurate n=11). TAVI using the transfemoral route was completed in 587 patients (Edwards SAPIEN/SAPIEN XT; n=399; Medtronic CoreValve n=188).
Out of 1000 patients, 1 patient in the transapical group (none in the transfemoral group) was lost to follow-up during the first year. The follow-up for the remaining 999 patients was complete, and the duration of follow-up was only determined 
Full Cohort
In a first step, we evaluated the full cohort of 1000 patients based on their assignment to transapical or transfemoral access. Patients undergoing transapical TAVI were less often female and had less pulmonary hypertension defined as systolic pressure of >60 mm Hg; Table 1 (Figure 2, top) was lower in the transapical than in the transfemoral group (log-rank test P=0.0388).
Mortality in risk groups was analyzed in the full cohort in patients having a 2 year follow-up because for this time frame, the complete cohort had a 99.9% follow-up (Table 3) . It was demonstrated that there were minor nominal differences in mortality between transapical and transfemoral TAVI with no statistically significant differences between groups, although the low power for this analysis is acknowledged. Table 1 illustrates that propensity ccore matching resulted in 2 groups of 354 patients each. Groups were well balanced with respect to patient characteristics, comorbid disease conditions, and risk as determined by the EuroSCORE.
Propensity Score-Matched Cohort
As in the full cohort, VARC II defined 30 day complications (Table 2) were largely comparable between groups, with no difference in 30 day mortality, the rate of MI, or stroke. Bleeding complications were not statistically different in the adjusted model as opposed to the full cohort. Furthermore, there were no differences in pacemaker implantation rates, but the increase in moderate aortic insufficiency in the transfemoral TAVI group remained significant (OR, 0.30; 95% CI, 0.10-0.93). Moderate aortic valve insufficiency was more frequent in the transfemoral group using the CoreValve (7.6%) versus the Edwards valves (1.7%) as was a need for pacemaker implantation (33.1 versus 21.6%); again complications were more because of the CoreValve use than for the Edwards valves.
Stage 1 renal complications continued to be more common in transapical patients (OR, 2.81; 95% CI, 1.93-4.09), whereas major vascular complications were less common (OR, 0.14; 95% CI, 0.06-0.29). Survival probability over the long term (Figure 2, bottom) was not statistically different in both groups (log-rank rest, P=0.27).
Landmark Analysis
To assess the outcomes of patients surviving the first 30 days, we conducted a landmark analysis (Figure 3) censoring all patients dying until then. We had 939 patients available for the full cohort (61 died within the first 30 days) and 408 patients for a propensity-matched cohort considering the 30 day outcomes as further variables. The analyses illustrate that, similar to the original survival analysis (Figure 2 ), there is a reduced survival in the transapical TAVI cohort in the full cohort before matching (HR, 0.79; 95% CI, 0.65-0.95) that becomes statistically nonsignificant after matching (HR, 0.81; 95% CI, 0.61-1.09) with a P value of 0.17 in the logrank test.
Discussion
Our analyses demonstrated a comparable major cardiovascular event rate at 30 days between transapical and transfemoral TAVI and a significant increased risk of death during the longterm follow-up with transapical TAVI. It seems, however, that this differential long-term risk may be based on the risk profile of transapical TAVI patients as compared with transfemoral TAVI patients, because after propensity score matching, the difference was not statistically significant. The results are in partial disagreement with earlier registry results, although it enforces other analyses. It seems reasonable to assume that this result can be attributed to the experience of this single high TAVI volume center with a transapical TAVI mortality that is less than in many other registries. There was an imbalance in major vascular complications and renal complications as well as moderate aortic insufficiency; however, that are specific for either access route.
Mortality
The 30-day mortality was 6.1% for transapical TAVI and 6.5% for transfemoral TAVI, which is substantially lower than in a Canadian registry (10.4%) 26 ; SOURCE (8.5%) 3 ; a FRANCE registry (12.7%) 4 ; a German registry (8.2%), 5 and slightly higher than in an Italian registry (5.4%). 6 In the PARTNER Trial (cohort B), 30-day mortality was 5%, and it was 5.2% in the PARTNER A cohort. 27, 28 In several clinical multicenter registries, 30-day mortality was usually higher in transapical patients than in those with transfemoral access. [2] [3] [4] [5] [6] [7] [8] The highest difference was observed in UK TAVR (11.2 versus 4.3%) and the lowest in SOURCE 1/2 (10.9 versus 7.5%). The highest mortality overall was observed in FRANCE2, where 30-day mortality rates with transapical TAVI were 13.9%. Against these data, the observed 30-day mortality in our cohort is comparable with the literature for transfemoral, although transapical mortality rates were rather low. 2 A probable explanation for the apparent higher 30-day mortality with the transapical access in other centers may be the learning curve that might be prolonged with transapical versus transfemoral. In a recent analysis of 439 transapical TAVI cases at the Leipzig Heart Center between 2006 and 2011, Holzhey et al 29 reported that short-and long-term mortality was substantially reduced if the first 120 patients were compared with the next 120 patients (patient 121-240), despite a higher EuroSCORE in the latter patient group (33% in the latter versus 29% in the earlier patient group). These data essentially confirm previous reports on an important effect of the learning curve on clinical outcomes. 30, 31 Particularly low 30-day transapical mortality rates were also published by Pasic in a single center series of 500 cases. 32 They reported a 30-day mortality rate of 4.6% with no significant change in the observational period between April 2008 and December 2011. This was attributed to a structured training program that was used to introduce transapical transcatheter aortic valve implantation and then gradually dispersed by internal proctoring.
Thirty-day and long-term mortality rates both were not statistically different after matching patients for patient characteristics using Propensity Scoring. Although this is in contrast to the majority of the aforementioned registries, it is comparable to other data reporting similar mortality rates for either access route. [11] [12] [13] [14] [15] [16] Johansson et al, for example, reported an overall 30-day mortality rate in a cohort of 40 patients of 5.0%, and differences between transapical and transfemoral in a propensity score-matched analysis were not significant. 11 However, Ewe et al 13 reported higher overall mortality rates for 30 days (transfemoral 11.1%, transapical 8.5%; P=0.74) with no difference between groups. Six and 12 months mortality rates were ≤20%, again with no difference between groups. Worth mentioning, Bleiziffer et al reported rather high mortality rates in a 203 patient cohort with 11.2% of patients dying within 30 days for the transfemoral and 8.3% for the transapical route. 15 In summary, it seems reasonable to conclude that short-and long-term mortality between transapical and transfemoral TAVI can be reduced in an experienced heart team and that procedural considerations may guide treatment decisions and influence complication rates.
Complications
Both techniques are associated with certain site-specific access complications that require immediate recognition and qualified management. Among those, previously reported events are major vascular complications 11 and cerebrovascular events. 12, 14 Our own analysis resulted in the key finding that major vascular complications (15.8 versus 2.5%; OR, 0.14-propensity-matched) and moderate aortic insufficiency (1.7 versus 1.2%; OR, 0.30) were more common in patients Major vascular complications associated with the transfemoral approach have been related to the large diameter introducer sheath and stiffness of the delivery system, in combination with vascular calcification and tortuosities in an elderly population (mean age in our cohort 82 years). A device with a smaller diameter was shown to reduce the risk of vascular access complications. 11 A specific analysis of transfemoralrelated vascular complications was published by Hayashida et al. 33 Using the sheath to femoral artery ratio, which was defined as the sheath outer diameter (in millimeters) to the minimal femoral artery diameter (in millimeters), they found that at a mean sheath to femoral artery ratio of 0.99±0.16 with a sheath to femoral artery ratio threshold of 1.05 (area under the curve =0.727) predicted a higher rate of VARC II major complications (30.9% versus 6.9%; P=0.001) and 30-day mortality (18.2% versus 4.2%; P=0.016). Therefore, a further improvement of transfemoral success and survival rates might relate to the prevention of major vascular events, which have been shown to affect survival. 33 Moderate/severe paravalvular leak is a frequent adverse outcome, which is described in the literature to occur in ≈3.4% of cases. 34 Paravalvular leak is usually detected during the procedure, immediately after valve deployment. It may diminish or disappear within a short time period; however, there is the possibility to improve the quality of the seal between the prosthesis and the native annulus by using postimplantation dilation and by an improved valve design. Rates of paravalvular leak can also be reduced by developments of the device, such as the third generation SAPIEN 3 valve with the COMMANDER (transfemoral access) and CERTITUDE delivery systems (transapical/transaortic access). Compared with the SAPIEN XT, it has a lower profile delivery system to reduce major vascular complications, 35, 36 a revised frame to maintain circularity, and a new outer skirt to decrease the risk of paravalvular leak. 37 Finally, stage 1 acute renal complications were more frequent in those undergoing transapical TAVI, and this confirms similar findings from other recent reports. 38, 39 Saia et al in particular investigated the incidence, predictors, and the clinical effect of acute kidney injury defined according to VARC II. In their single-center cohort of 102 consecutive patients, 42 developed periprocedural acute renal complications with 32.4% in stage 1, 4.9% in stage 2, and 3.9% at stage 3. This occurred almost twice as often in transapical (66.7%) than in transfemoral (30.3%) procedures. The only independent predictor of acute kidney injury was transapical access, with a hazard ratio between 4.57 and 5.18 based on the model used. Only stage 3 translated into a meaningful effect on 1-year mortality.
Limitations
The most important limitation of the present study is the lack of a random assignment to treatment groups. Evaluating the effect of a specific treatment using a registry can lead to incorrect conclusions because of the influence of unknown confounding variables. Because there are no randomized, controlled trials comparing either access route to date, we had to adjust for known differences in baseline variables using the propensity score. This method is usually accurate to eliminate differences between groups, but there is a potential for unconsidered or even unknown confounders that were not considered. So there is a residual risk that a potential learning curve that might be different for transapical and transfemoral could influence the result. A further limitation is the missing adjustment for valve types (Symetis Acurate, Edwards SAPIEN/SAPIEN XT, Medtronic CoreValve). We were not able to consider these for propensity matching, and because they were not equally distributed between groups, they may have had an effect on the results, which generally relates to complications, such as pacemaker implantations or aortic insufficiency. Finally, we are a high volume center with vast experience in doing both transapical and transfemoral TAVI. It can be expected that we have optimized our implant technique for either access route considerably and thus the results may not apply to low volume centers where one approach may need more experience than the other to perform equally well.
Conclusions
The present single-center, consecutive case series of 1000 patients undergoing transfemoral or transapical transcatheter aortic valve implantation demonstrated that there is no statistically significant incremental mortality risk using the transapical versus the transfemoral access route in a high volume center when compared using propensity score matching. Major vascular complications and aortic insufficiency were more common in patients undergoing transfemoral TAVI and stage 1 acute renal complications in those with transapical TAVI. The data demonstrate that an experienced multidisciplinary heart team can consistently and safely perform TAVI by either access route.
